clinical trial · NCT04837040
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly
AcromegalyPaltusotinePlacebo
brief summary
A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (also known as CRN00808; an orally administered nonpeptide somatostatin agonist) in subjects with acromegaly previously treated with somatostatin receptor ligand (SRL) based treatment regimens.
started
May 12, 2021
primary completion
Jul 10, 2023
completion
May 29, 2026
last updated
Jul 15, 2026
official title
A Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects With Acromegaly Treated With Long-acting Somatostatin Receptor Ligands (PATHFNDR-1)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol